MRI findings and pathological features in early-stage glioblastoma

详细信息    查看全文

• 作者：Makoto Ideguchi ; Koji Kajiwara ; Hisaharu Goto…
• 关键词：MRI ; Early ; stage ; Glioblastoma ; IDH1 ; de novo type ; Secondary type
• 刊名：Journal of Neuro-Oncology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：123
• 期：2
• 页码：289-297
• 全文大小：1,726 KB
• 参考文献：1.Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436-40View Article PubMed
  2.Oyama H, Ando Y, Aoki S, Kito A, Maki H, Hattori K, Tanahashi K (2010) Glioblastoma detected at the initial stage in its developmental process case report. Neurol Med Chir (Tokyo) 50:414-17View Article
  3.Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65-3View Article PubMed
  4.Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K (2012) Glioblastoma without remarkable contrast enhancement on magnetic resonance imaging. ICJM 3:439-45. doi:10.-236/?ijcm.-012.-6082
  5.Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-453. doi:10.-353/?ajpath.-007.-70011 View Article PubMed Central PubMed
  6.Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892-899. doi:10.-158/-008-5472.?CAN-04-1337 View Article PubMed
  7.Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65-2View Article PubMed
  8.Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539-43PubMed
  9.Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-02. doi:10.-007/?s00401-008-0455-2 View Article PubMed
  10.Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-153. doi:10.-353/?ajpath.-009.-80958 View Article PubMed Central PubMed
  11.Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-73View Article PubMed Central PubMed
  12.Louis DN, Ohgaki H, Weistler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. 4th edn. IARC Press, Lyon
  13.Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-857PubMed
  14.Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655-67View Article PubMed
  15.Chang KW, Sarraj S, Lin SC, Tsai PI, Solt D (2000) P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis 21:1441-451View Article PubMed
  16.Kramar F, Zemanova Z, Michalova K, Babicka L, Ransdorfova S, Hrabal P, Kozler P (2007) Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. J Neurooncol 84:201-11. doi:10.-007/?s11060-007-9358-7 View Article PubMed
  17.Wharton SB, Maltby E, Jellinek DA, Levy D, Atkey N, Hibberd S, Crimmins D, Stoeber K, Williams GH (2007) Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol 113:119-27. doi:10.-007/?s00401-006-0177-2 View Article PubMed Central PubMed
  18.Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764-72. doi:10.-158/-078-0432.?CCR-12-3002 View Article PubMed
  19.Cohen-Gadol AA, DiLuna ML, Bannykh SI, Piepmeier JM, Spencer DD (2004) Non- enhancing de novo glioblastoma: report of two cases. Neurosurg Rev 27:281-85. doi:10.-007/?s10143-004-0346-5 View Article PubMed
  20.Okamoto K, Ito J, Takahashi N, Ishikawa K, Furusawa T, Tokiguchi S, Sakai K (2002) MRI of high-grade astrocytic tumors: early appearance and evolution. Neuroradiology 44:395-02. doi:10.-007/?s00234-001-0725-3 View Article PubMed
  21.Landy HJ, Lee TT, Potter P, Feun L, Markoe A (2000) Early MRI findings in high grade glioma. J Neurooncol
• 作者单位：Makoto Ideguchi (1)
  Koji Kajiwara (2)
  Hisaharu Goto (1)
  Kazutaka Sugimoto (1)
  Sadahiro Nomura (1)
  Eiji Ikeda (3)
  Michiyasu Suzuki (1)
  
  1. Department of Neurosurgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-kogushi, Ube, Yamaguchi, 755-8505, Japan
  2. Department of Neurosurgery, Ube-nishi Rehabilitation Hospital, Ube, Japan
  3. Department of Pathology, Yamaguchi University Graduate School of Medicine, Ube, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7373

文摘

Magnetic resonance imaging (MRI) is an important diagnostic tool for glioblastoma, with almost all cases showing characteristic imaging findings such as a heterogeneous-ring enhanced pattern associated with significant edema. However, MRI findings for early-stage glioblastoma are less clear. In this study, a retrospective review of MRI findings in five patients showed slight T2WI signal changes on initial scans that developed into typical imaging findings of a ring-like or heterogeneously enhanced bulky tumor within 6?months. The diagnoses based on initial MRI were low grade glioma in three cases, venous thrombosis in one case, and uncertain in one case. Four cases were treated with gross total resection, while one case underwent biopsy. Immunohistochemical examinations showed that two cases were p53-positive, and that all cases were IDH1 R132H-negative and had overexpression of EGFR. FISH analysis showed that all cases were 1p19q LOH-negative. De novo glioblastoma was the final diagnosis in all cases. Our results show that initial MRI findings in early-stage glioblastoma of small ill-defined T2WI hyperintense lesions with poor contrast develop to bulky mass lesions with typical findings for glioblastoma in as short a period as 2.5?months. The early MRI findings are difficult to distinguish from those for non-neoplastic conditions, including ischemic, degenerative or demyelinating processes. Thus, there is a need for proactive diagnosis of glioblastoma using short-interval MRI scans over several weeks, other imaging modalities, and biopsy or resection, particularly given the extremely poor prognosis of this disease.